论文部分内容阅读
业已证明,血浆C-反应蛋白(CRP)升高与心血管病危险增加有关。本文拟就长程降脂药普伐它汀对心血管病危险因素之——炎症反应物血浆CRP的可能作用进行了评估。对象与方法 472例急性心肌梗死(AMI)后患者,年龄21～75岁。先期剔除血浆CRP异常升高者。研究期间分为随机双盲服用普伐它汀40mg/d的治疗组258例,和仅服安慰剂的对照组214例,持续长程用药并人均随访5年,此间无1例再发冠脉意外。嗣后比较两组入选时与5年后血浆CRP变化的差异。
It has been demonstrated that elevated plasma C-reactive protein (CRP) is associated with an increased risk of cardiovascular disease. This article is intended to evaluate the potential role of pravastatin, a long-acting lipid-lowering drug, in the plasma CRP, a cardiovascular risk factor that is an inflammatory response. Subjects and Methods 472 patients with acute myocardial infarction (AMI), aged 21 to 75 years old. Premature exclusion of abnormal plasma CRP. The study was divided into randomized double-blind treatment with pravastatin 40mg / d in 258 patients and placebo-only control group 214 patients, sustained long-term medication and per capita follow-up of 5 years, none of the cases of recurrent coronary artery disease . We then compared the differences in plasma CRP between the two groups when they were enrolled and after 5 years.